Menu Search
Equities

ProQR Therapeutics NV

0PQ:BER

ProQR Therapeutics NV

Actions
  • Price (EUR)3.67
  • Today's Change0.02 / 0.55%
  • Shares traded--
  • 1 Year change+181.66%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 07:03 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).

  • Revenue in USD (TTM)19.76m
  • Net income in USD-22.76m
  • Incorporated2012
  • Employees157.00
  • Location
    ProQR Therapeutics NVZernikedreef 9LEIDEN 2333 CKNetherlandsNLD
  • Phone+31 854894932
  • Websitehttps://www.proqr.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.